Prognostic value of serum vascular endothelial growth factor and hematological responses in patients with newly-diagnosed POEMS syndrome

作者：Hao Zhao, Hao Cai, Chen Wang, Xufei Huang, Xinxin Cao, Lu Zhang, Daobin Zhou, Li J · 发表于：Blood Cancer Journal · 年份：2018 · DOI：10.1038/s41408-018-0073-8 · 被引用次数：24 · 研究领域：Peripheral Neuropathies and Disorders、Long-Term Effects of COVID-19、Vasculitis and related conditions

Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes (POEMS) syndrome is a rare plasma cell dyscrasia characterized by high serum levels of vascular endothelial growth factor (VEGF) 1 , 2 . Bone marrow plasma cells are the likely source of this angiogenic cytokine, which is responsible for the characteristic symptoms of this disorder, including extra-vascular volume overload, hemagiomata and papilledema. A reduction of VEGF level after treatment usually correlates with symptomatic improvement 3 , 4 , 5 , 6 . The main treatment strategy is to target plasma cell clones, and monoclonal protein and VEGF levels are used to monitor disease activity.